High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
Crossref DOI link: https://doi.org/10.1186/s13045-016-0363-1
Published Online: 2016-11-30
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Falchi, Lorenzo
Sawas, Ahmed
Deng, Changchun
Amengual, Jennifer E.
Colbourn, Donald S.
Lichtenstein, Emily A.
Khan, Karen A.
Schwartz, Lawrence H.
O’Connor, Owen A.
Funding for this research was provided by:
None (Not applicable)